<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01152749</url>
  </required_header>
  <id_info>
    <org_study_id>NICTDP1075</org_study_id>
    <secondary_id>2009-010633-44</secondary_id>
    <nct_id>NCT01152749</nct_id>
  </id_info>
  <brief_title>Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum</brief_title>
  <official_title>Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum. A Study in Healthy Smokers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the bioequivalence between an oral nicotine replacement product and
      Nicorette® gum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a single-dose, randomized, crossover study with 76 subjects (all subjects will
      receive all treatments). The investigational products will be given as single doses at
      separate treatment visits. Periods without Nicotine Replacement Therapy (NRT), lasting for at
      least 36 hours, will separate treatment visits. Blood for pharmacokinetic analyses will be
      drawn before and at 5, 10, 15, 20, 30, 45, and 60 minutes, as well as at 1.5, 2, 4, 6, 8, and
      10 hours after start of product administration. Used gums will be collected and analyzed to
      determine the amount of remaining nicotine. Subjects will also be monitored to capture any
      adverse events that may occur.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic measurements</measure>
    <time_frame>Baseline and during 10 hours after product administration</time_frame>
    <description>Pharmacokinetic measurements including:
the maximum observed nicotine concentration in plasma (Cmax)
the area under the plasma concentration-vs.-time curve until the last measurable concentration (AUCt)
the area under the plasma concentration-vs.-time curve until infinity (AUC∞)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>Baseline and during 10 hours after product administration</time_frame>
    <description>The time of occurrence of Cmax following product administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lamda z</measure>
    <time_frame>Baseline and during 10 hours after product administration</time_frame>
    <description>The terminal nicotine elimination rate constant (λz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Released amount of nicotine</measure>
    <time_frame>After 30 minutes of chewing</time_frame>
    <description>The amount of nicotine released from gums during 30 minutes' chewing.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>UNG-GC-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg experimental NRT product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UNG-GC-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg experimental NRT product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicorette® Gum-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 mg Nicorette® Gum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicorette® Gum-4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg Nicorette® Gum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Single-dose of new NRT product</description>
    <arm_group_label>UNG-GC-2</arm_group_label>
    <arm_group_label>UNG-GC-4</arm_group_label>
    <other_name>Nicotine NRT / not yet marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Gum</intervention_name>
    <description>Single-dose of marketed nicotine gum</description>
    <arm_group_label>Nicorette® Gum-2</arm_group_label>
    <arm_group_label>Nicorette® Gum-4</arm_group_label>
    <other_name>Nicorette® Gum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects, smoking at least 10 cigarettes daily during at least one year
             preceding inclusion and body mass index (BMI) between 17.5 and 30.0 kg/m2.

          -  Female participants of child-bearing potential are required to use a medically
             acceptable means of birth control.

          -  A personally signed and dated informed consent document, indicating that the subject
             has been informed of all pertinent aspects of the study.

        Exclusion Criteria:

          -  Pregnancy, lactation or intended pregnancy.

          -  Treatment with an investigational product or donation or loss of blood within 3 month
             preceding the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Kruse, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McNeil AB Clinical Pharmacology R&amp;D</name>
      <address>
        <city>Lund</city>
        <zip>SE-222 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2010</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Nicotine pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

